Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Otsuka to take advantage of newly charted accelerated pathway for IgA nephropathy

BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more

October 22, 2024 10:22 PM UTC

An interim readout from a Phase III study may suffice for Otsuka to obtain FDA approval of sibeprenlimab, setting up the anti-APRIL antibody as a possible first-in-class entrant in IgA nephropathy.

Otsuka Holdings Co. Ltd. (Tokyo:4578) said Tuesday that an interim analysis showed sibeprenlimab met the study’s primary endpoint of proteinuria, which has previously served as a surrogate endpoint supporting accelerated approval of other treatments for IgA nephropathy. The pharma did not release detailed data on the outcome, which measured 24-hour urine protein-to-creatine ratio at nine months compared with placebo...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article